Live webcasts of the presentations at the Wells Fargo and Ladenburg Thalmann conferences may be accessed from the News & Events section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic T cell therapies. Bellicum's lead GoCAR-T^® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. Bellicum's rivo-cel product candidate is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. For additional information about the company, please visit bellicum.com.